Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Benin is experiencing a steady growth in recent years.
Customer preferences: Benin has a population that is aging rapidly, which has led to an increase in the prevalence of cardiovascular diseases. This has resulted in an increased demand for anti-coagulants, which are used to prevent blood clots and reduce the risk of stroke and heart attack. Additionally, there is a growing awareness of the benefits of anti-coagulants among the general population, which has further contributed to the growth of the market.
Trends in the market: One of the major trends in the Anti-Coagulants market in Benin is the increasing adoption of novel oral anti-coagulants (NOACs). These drugs have several advantages over traditional anti-coagulants, such as lower risk of bleeding and fewer drug interactions. As a result, there has been a shift towards NOACs in recent years, which has contributed to the growth of the market. Another trend in the market is the increasing use of anti-coagulants for indications other than stroke and heart attack, such as deep vein thrombosis and pulmonary embolism.
Local special circumstances: One of the unique characteristics of the Anti-Coagulants market in Benin is the high cost of treatment. This has made it difficult for many patients to access the drugs they need, particularly those from low-income backgrounds. As a result, there is a growing need for affordable anti-coagulants in the market. Additionally, there is a lack of awareness among healthcare professionals about the benefits of NOACs, which has resulted in a slower adoption rate compared to other countries.
Underlying macroeconomic factors: The growth of the Anti-Coagulants market in Benin is driven by several macroeconomic factors. One of the key drivers is the increasing prevalence of cardiovascular diseases, which is linked to the aging population and changing lifestyle habits. Additionally, the government has implemented several policies to improve healthcare access and infrastructure, which has contributed to the growth of the market. However, the market is also facing challenges such as high treatment costs and a lack of awareness among healthcare professionals, which may limit its growth in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
